(19)
(11) EP 2 763 697 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
12.07.2023 Bulletin 2023/28

(45) Mention of the grant of the patent:
07.06.2023 Bulletin 2023/23

(21) Application number: 12780309.6

(22) Date of filing: 04.10.2012
(51) International Patent Classification (IPC): 
A61K 39/39(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 2039/55511; A61K 47/50; A61K 47/62; A61K 47/6801; A61K 39/39; A61P 37/04
(86) International application number:
PCT/NL2012/050694
(87) International publication number:
WO 2013/051936 (11.04.2013 Gazette 2013/15)

(54)

ADJUVANT COMPOUND

ADJUVANZIENVERBINDUNG

COMPOSÉ ADJUVANT


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 05.10.2011 NL 2007536
05.10.2011 US 201161543510 P
26.03.2012 US 201261615566 P

(43) Date of publication of application:
13.08.2014 Bulletin 2014/33

(73) Proprietor: ISA Pharmaceuticals B.V.
2342 DH Oegstgeest (NL)

(72) Inventors:
  • OSSENDORP, Ferdinand Antonius
    1182 CT Amstelveen (NL)
  • MELIEF, Cornelis Johannes Maria
    2012 KC Haarlem (NL)
  • KHAN, Selina
    2312HK Leiden (NL)
  • FILIPPOV, Dmitri Viktorovitsj
    2334 EV Leiden (NL)
  • VAN DER MAREL, Gijsbert Arie
    2318 MD Leiden (NL)

(74) Representative: Nederlandsch Octrooibureau 
P.O. Box 29720
2502 LS The Hague
2502 LS The Hague (NL)


(56) References cited: : 
EP-A1- 0 431 327
   
  • TSUNEAKI HIDA ET AL: "Synthesis and Biological Activities of TAN-1511 Analogues.", THE JOURNAL OF ANTIBIOTICS, vol. 48, no. 7, 1 January 1995 (1995-01-01), pages 589-603, XP055023889, ISSN: 0021-8820, DOI: 10.7164/antibiotics.48.589
  • MOYLE PETER M ET AL: "Self-adjuvanting lipopeptide vaccines", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 15, no. 5, 1 January 2008 (2008-01-01), pages 506-516, XP009104575, ISSN: 0929-8673, DOI: 10.2174/092986708783503249
  • SPOHN R ET AL: "Synthetic lipopeptide adjuvants and Toll-like receptor 2-structure-activity relationships", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 19, 23 June 2004 (2004-06-23) , pages 2494-2499, XP004515469, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2003.11.074
  • ZAMAN M ET AL: "Immunostimulation by Synthetic Lipopeptide-Based Vaccine Candidates: Structure-Activity Relationships", FRONTIERS IN IMMUNOLOGY, vol. 4, 9 October 2013 (2013-10-09), XP055570911, DOI: 10.3389/fimmu.2013.00318
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).